secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001140361-23-039412
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Q2 net loss $9.2M; NAVIGATE trial interim analysis expected Q4 2024
----------------------------------------------------------------------------

- Net loss per share $0.15 for Q2 2023 vs $0.16 in Q2 2022; R&D expenses $7.4M down from $8.1M.
- Cash and equivalents $18.0M as of June 30, 2023; additional $30M available under chairman's credit line.
- NAVIGATE trial (NASH cirrhosis) fully randomized with 357 patients; Phase 2b interim analysis expected Q4 2024.
- Company evaluating Phase 2 trial of belapectin plus Keytruda in advanced head and neck cancers.
- Belapectin safety profile remains encouraging; no approved therapy for NASH cirrhosis with portal hypertension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/0001140361-23-039412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/brhc20057380_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-039412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer